Viralgen and Trogenix to progress gene therapy for glioblastoma
Contract development and manufacturing organisation (CDMO) Viralgen has partnered biotech company Trogenix to accelerate the development of a recombinant adeno-associated…
Contract development and manufacturing organisation (CDMO) Viralgen has partnered biotech company Trogenix to accelerate the development of a recombinant adeno-associated…
Immunic will continue developing its multiple sclerosis (MS) drug, vidofludimus calcium (IMU-838), despite a Phase II trial missing its primary…
Neurocrine Biosciences has commenced a Phase III registrational programme to assess investigational oral muscarinic M4 selective orthosteric agonist NBI-1117568 as…
US-based biotechnology company Therini Bio has reported positive results from a Phase Ia trial of THN391, a potential treatment for…
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported topline outcomes from the Phase III ARISE trial of Cobenfy as…
Give your business an edge with our leading industry insights.
Alector has completed subject enrolment in the 76-week, randomised, Phase II PROGRESS-AD trial, which is assessing the efficacy and safety…
Australia-based Neuren Pharmaceuticals has confirmed the primary goals for its double-blind, single Phase III pivotal trial of its drug NNZ-2591…
US-based Alzheon’s Alzheimer’s disease pill has failed in a Phase III trial, but the biopharma still holds hope for the…
The month of April is dedicated to raising awareness of Parkinson’s disease (PD), the main aim of which is to…
On 8 April, at the 2025 American Academy of Neurology (AAN) meeting, Johnson & Johnson (J&J) announced results from additional…